CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 96 enrolled
Drug / intervention
Levetiracetam 62.5mg +3 moredrug
Likely dose
Levetiracetam 62.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01044758
NCT01044758Phase 2Completed
CompareCT.gov

Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI

Johns Hopkins University·interventional·Posted Jan 8, 2010·Updated Aug 21, 2017

In Brief

A Phase 2 clinical trial evaluating Levetiracetam 62.5mg, Levetiracetam 125mg, and 2 other interventions for Mild Cognitive Impairment (MCI). Completed, enrolled 96 participants across 1 site.

Detailed Summary

This research is being done to find out if daily use of the drug levetiracetam can improve memory function in individuals with memory problems like those associated with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment (MCI)
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 8, 2010
Enrollment StartDec 1, 2009
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 16.5 years ago

Interventions

Levetiracetam 62.5mgdrug

62.5mg twice daily (2 weeks)

Levetiracetam 125mgdrug

125mg twice daily (2 weeks)

Levetiracetam 250mgdrug

250mg twice daily (2 weeks)

Placebodrug

placebo capsule twice daily (2 weeks)